About US
Contact us
-
Generic Drugs Make Up 78% of All US PrescriptionsGeneric drugs made up 78% of all prescriptions dispensed in the US last year, a 4% increase from 2009, a report by the IMS Institute for Healthcare Informatics has shown. The report revealed that h2011/4/21
-
CO2: Climate Killer or Raw Material?20 April 2011 In the context of the "Green Technologies Day" event series initiated by Lewa, at the end of March participants were intensively discussing the question of whether CO2 should be seen2011/4/21
-
Welcome to ExcipientFest AmericasMay 10 - 11, 2011 - Renaissance Harborplace Hotel, Baltimore, MD Pharma Industry's BEST Event for Regulatory, Science and Sourcing Education ExcipientFest attracts Pharmaceutical Scientists fro2011/4/20
-
Weight-Loss Drugs Alli and Xenical Should Be Removed from the Market, Public Citizen Tells FDAWASHINGTON, April 14 -- Public Citizen issued the following news release: The over-the-counter weight-loss drug Alli and its prescription form Xenical should be removed from the market immediately2011/4/20
-
BT PUSHES FOR R&D INNOVATION AT BIO-IT WORLD CONFERENCEBT shared its vision of the future of pharma R&D and the application of cloud computing strategies to pharma research at the Bio-IT World Conference & Expo held this week in Boston. This visio2011/4/20
-
American Regent Recalls Multiple Productsof Shirley, N.Y. announced voluntary recalls of certain lots of multiple injectable products in March. The recalls include lots of concentrated sodium chloride injection, bacteriostatic sodium chlorid2011/4/19
-
EU Recommendation for Lilly and Amylin Diabetes DrugExperimental diabetes drug Bydureon, developed by Eli Lilly and Amylin Pharmaceuticals, has been recommended for approval by the European Medicines Agency. Bydureon is a longer-acting version of B2011/4/19
-
Eli Lilly receives FDA complete response letter for liprotamase NDAEli Lilly and Company (NYSE: LLY) has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for liprotamase, a non-porcine pancreatic2011/4/18
-
Johnson & Johnson provides further details regarding distribution rights for REMICADE, SIMPONIJohnson & Johnson (NYSE: JNJ) provided additional information today on its amended agreement with Merck regarding distribution rights for REMICADE® (infliximab) and SIMPONI® (golimumab) in2011/4/18
-
Sanofi Reports Positive Results from Diabetes Drug StudySanofi-Aventis has reported positive results from the Phase III study evaluating lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes. The study achi2011/4/18